Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/a-perspective-on-modelling-hepatitis-c-virus-infection-iGS7ObgUf0
References (74)
-
B. Adiwijaya, B. Hare, P. Caron, J. Randle, A. Neumann, H. Reesink, S. Zeuzem, E. Herrmann (2008)
Rapid decrease of wild-type hepatitis C virus on telaprevir treatmentAntiviral Therapy, 14
-
Hepatitis C . Fact sheet No . 164 . Revised October 2000 -
J. Pawlotsky, S. Chevaliez, J. McHutchison (2007)
The hepatitis C virus life cycle as a target for new antiviral therapies.Gastroenterology, 132 5
-
M. Lobanov, E. Furletova, N. Bogatyreva, M. Roytberg, O. Galzitskaya (2010)
Library of Disordered Patterns in 3D Protein StructuresPLoS Computational Biology, 6
-
E. Borden, G. Sen, G. Uzé, R. Silverman, R. Ransohoff, G. Foster, G. Stark (2007)
Interferons at age 50: past, current and future impact on biomedicineNature Reviews. Drug Discovery, 6
-
A. Talal, R. Ribeiro, K. Powers, M. Grace, C. Cullen, M. Hussain, M. Markatou, A. Perelson (2006)
Pharmacodynamics of PEG‐IFN α differentiate HIV/HCV coinfected sustained virological responders from nonrespondersHepatology, 43
-
J. Cuevas, F. González-Candelas, A. Moya, R. Sanjuán (2009)
Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In VivoJournal of Virology, 83
-
Tara Kieffer, C. Sarrazin, Janice Miller, M. Welker, N. Forestier, H. Reesink, A. Kwong, S. Zeuzem (2007)
Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patientsHepatology, 46
-
Jeremie Guedj, Rodolphe Thiébaut, Daniel Commenges (2007)
Maximum Likelihood Estimation in Dynamical Models of HIVBiometrics, 63
-
N. Forestier, H. Reesink, C. Weegink, L. Mcnair, Tara Kieffer, H. Chu, S. Purdy, P. Jansen, S. Zeuzem (2007)
Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis CHepatology, 46
-
(1996)
Biological significance of viral quasispecies -
P. Glue, J. Fang, R. Rouzier-Panis, C. Raffanel, R. Sabo, S. Gupta, M. Salfi, S. Jacobs (2000)
Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.Clinical pharmacology and therapeutics, 68 5
-
A. Perelson, E. Herrmann, Florence Micol, S. Zeuzem (2005)
New kinetic models for the hepatitis C virusHepatology, 42
-
B. Adiwijaya, E. Herrmann, B. Hare, Tara Kieffer, Chao Lin, A. Kwong, V. Garg, J. Randle, C. Sarrazin, S. Zeuzem, P. Caron (2010)
A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant VariantsPLoS Computational Biology, 6
-
H. Dahari, M. Major, Xinan Zhang, K. Mihalik, C. Rice, A. Perelson, S. Feinstone, A. Neumann (2005)
Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production.Gastroenterology, 128 4
-
R. Sentjens, C. Weegink, M. Beld, M.C.H. Cooreman, H. Reesink (2002)
Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha dailyEuropean Journal of Gastroenterology & Hepatology, 14
-
C. Sarrazin, Tara Kieffer, D. Bartels, B. Hanzelka, U. Müh, M. Welker, D. Wincheringer, Yi Zhou, H. Chu, Chao Lin, C. Weegink, H. Reesink, S. Zeuzem, A. Kwong (2007)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.Gastroenterology, 132 5
-
U. Mihm, E. Herrmann, C. Sarrazin, S. Zeuzem (2006)
Review article: predicting response in hepatitis C virus therapyAlimentary Pharmacology & Therapeutics, 23
-
K. Powers, N. Dixit, R. Ribeiro, Preeti Golia, A. Talal, A. Perelson (2003)
Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b.Seminars in liver disease, 23 Suppl 1
-
B. Lindenbach, C. Rice (2005)
Unravelling hepatitis C virus replication from genome to functionNature, 436
-
E. Herrmann, S. Zeuzem, C. Sarrazin, H. Hinrichsen, Y. Benhamou, M. Manns, M. Reiser, H. Reesink, J. Calleja, X. Forns, G. Steinmann, G. Nehmiz (2005)
Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061Antiviral Therapy, 11
-
M. Buti, F. Sánchez-Ávila, Y. Lurie, Carlos Stalgis, A. Valdés, M. Martell, R. Esteban (2002)
Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa‐2b plus ribavirinHepatology, 35
-
P. Jafari, S. Ayatollahi, Javad Behboodian (2006)
Sequential boundaries approach in clinical trials with unequal allocation ratiosBMC Medical Research Methodology, 6
-
T. Awad, K. Thorlund, G. Hauser, D. Štimac, M. Mabrouk, C. Gluud (2010)
Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: Systematic review of randomized trialsHepatology, 51
-
N. Holford, L. Sheiner (1982)
Kinetics of pharmacologic response.Pharmacology & therapeutics, 16 2
-
World Health Organization. Hepatitis C. Fact sheet No. 164 -
D. Callaway, A. Perelson (2002)
HIV-1 infection and low steady state viral loadsBulletin of Mathematical Biology, 64
-
E. Shudo, R. Ribeiro, A. Perelson (2008)
Modelling hepatitis C virus kinetics during treatment with pegylated interferon α‐2b: errors in the estimation of viral kinetic parametersJournal of Viral Hepatitis, 15
-
(2000)
The 2nd phase slope of HCV decline is highly predictive of sustained virologic response following consensus IFN treatment for chronic hepatitis C and is determined by genotype but not dose -
N. Dixit, A. Perelson (2004)
Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay.Journal of theoretical biology, 226 1
-
H. Dahari, B. Sáinz, A. Perelson, S. Uprichard (2009)
Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha InterferonJournal of Virology, 83
-
E. Formann, W. Jessner, L. Bennett, P. Ferenci (2003)
Twice‐weekly administration of peginterferon‐α‐2b improves viral kinetics in patients with chronic hepatitis C genotype 1Journal of Viral Hepatitis, 10
-
L. Guidotti, R. Rochford, Josan Chung, M. Shapiro, R. Purcell, F. Chisari (1999)
Viral clearance without destruction of infected cells during acute HBV infection.Science, 284 5415
-
J. Layden, T. Layden, K. Reddy, Rachel Levy-Drummer, J. Poulakos, A. Neumann (2002)
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral declineJournal of Viral Hepatitis, 9
-
H. Dahari, J. Layden-Almer, E. Kallwitz, R. Ribeiro, S. Cotler, T. Layden, A. Perelson (2009)
A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.Gastroenterology, 136 4
-
E. Herrmann, Jung-H. Lee, G. Marinos, M. Modi, S. Zeuzem (2003)
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferonHepatology, 37
-
Chao Lin, C. Gates, B. Rao, D. Brennan, J. Fulghum, Y. Luong, J. Frantz, Kai Lin, Sue Ma, Yunyi Wei, R. Perni, A. Kwong (2005)
In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061*Journal of Biological Chemistry, 280
-
R. Bruno, P. Sacchi, V. Ciappina, Cristina Zochetti, S. Patruno, L. Maiocchi, G. Filice (2003)
Viral Dynamics and Pharmacokinetics of Peginterferon Alpha-2A and Peginterferon Alpha-2B in Naive Patients with Chronic Hepatitis C: A Randomized, Controlled StudyAntiviral Therapy, 9
-
F. Bekkering, J. Brouwer, B. Hansen, S. Schalm (2001)
Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin.Journal of hepatology, 34 3
-
K. Sherman, N. Shire, S. Rouster, M. Peters, Margaret Koziel, R. Chung, P. Horn (2005)
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.Gastroenterology, 128 2
-
F. Bekkering, A. Neumann, J. Brouwer, Rachel Levi-Drummer, S. Schalm (2001)
Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control studyBMC Gastroenterology, 1
-
H. Alter (2005)
HCV natural history: the retrospective and prospective in perspective.Journal of hepatology, 43 4
-
A. Neumann, N. Lam, H. Dahari, D. Gretch, T. Wiley, T. Layden, A. Perelson (1998)
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyScience, 282
-
H. Dahari, A. Lo, R. Ribeiro, A. Perelson (2007)
Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.Journal of theoretical biology, 247 2
-
A. Neumann, V. Bain, E. Yoshida, K. Patel, E. Pulkstenis, G. Subramanian (2009)
Early prediction of sustained virological response at day 3 of treatment with albinterferon‐α‐2b in patients with genotype 2/3 chronic hepatitis CLiver International, 29
-
R. Thiébaut, J. Guedj, H. Jacqmin-Gadda, G. Chêne, P. Trimoulet, D. Neau, D. Commenges (2006)
Estimation of dynamical model parameters taking into account undetectable marker valuesBMC Medical Research Methodology, 6
-
E. Shudo, R. Ribeiro, A. Talal, A. Perelson (2008)
A Hepatitis C Viral Kinetic Model that Allows for Time-Varying Drug EffectivenessAntiviral Therapy, 13
-
J. McHutchison, G. Everson, S. Gordon, I. Jacobson, M. Sulkowski, R. Kauffman, L. Mcnair, J. Alam, A. Muir (2009)
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.The New England journal of medicine, 360 18
-
J. Feld, J. Hoofnagle (2005)
Mechanism of action of interferon and ribavirin in treatment of hepatitis CNature, 436
-
S. Lewin, R. Ribeiro, T. Walters, G. Lau, S. Bowden, S. Locarnini, A. Perelson (2001)
Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observedHepatology, 34
-
S. Zeuzem, C. Welsch, E. Herrmann (2003)
Pharmacokinetics of PeginterferonsSEMINARS IN LIVER DISEASE, 23
-
H. Dahari, R. Ribeiro, C. Rice, A. Perelson (2006)
Mathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 CellsJournal of Virology, 81
-
A. Neumann, A. Neumann, N. Lam, H. Dahari, H. Dahari, M. Davidian, T. Wiley, Brian Mika, A. Perelson, T. Layden (2000)
Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.The Journal of infectious diseases, 182 1
-
H. Reesink, G. Fanning, K. Farha, C. Weegink, A. Vliet, G. Klooster, O. Lenz, F. Aharchi, K. Mariën, P. Remoortere, Herman Kock, F. Broeckaert, P. Meyvisch, Els Beirendonck, K. Simmen, R. Verloes (2010)
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.Gastroenterology, 138 3
-
Timothy Reluga, H. Dahari, A. Perelson (2009)
Analysis of Hepatitis C Virus Infection Models with Hepatocyte HomeostasisSIAM journal on applied mathematics, 69 4
-
Cong Han, K. Chaloner (2004)
Bayesian Experimental Design for Nonlinear Mixed‐Effects Models with Application to HIV DynamicsBiometrics, 60
-
Eileen Foy, Kui Li, Chunfu Wang, R. Sumpter, M. Ikeda, S. Lemon, M. Gale (2003)
Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine ProteaseScience, 300
-
Vincent Carey, You-Gan Wang (2001)
Mixed-Effects Models in S and S-PlusJournal of the American Statistical Association, 96
-
H. Dahari, J. Layden-Almer, A. Perelson, T. Layden (2008)
Hepatitis C viral kinetics in special populationsCurrent Hepatitis Reports, 7
-
C. Hézode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J. Bronowicki, M. Bourliere, S. Gharakhanian, L. Bengtsson, L. Mcnair, S. George, Tara Kieffer, A. Kwong, R. Kauffman, J. Alam, J. Pawlotsky, S. Zeuzem (2009)
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.The New England journal of medicine, 360 18
-
M. Silva, J. Poo, F. Wagner, Mary Jackson, D. Cutler, M. Grace, R. Bordens, C. Cullen, J. Harvey, M. Laughlin (2006)
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).Journal of hepatology, 45 2
-
D. Ge, J. Fellay, A. Thompson, J. Simon, K. Shianna, T. Urban, E. Heinzen, P. Qiu, A. Bertelsen, A. Muir, M. Sulkowski, J. McHutchison, D. Goldstein (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 461
-
H. Wu, A. Ding, V. Gruttola (1998)
Estimation of HIV dynamic parameters.Statistics in medicine, 17 21
-
Gustine Liu-Young, M. Kozal (2008)
Hepatitis C protease and polymerase inhibitors in development.AIDS patient care and STDs, 22 6
-
H. Dahari, E. Araujo, B. Haagmans, T. Layden, S. Cotler, A. Barone, A. Neumann (2010)
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.Journal of hepatology, 53 3
-
H. Dahari, E. Shudo, S. Cotler, T. Layden, A. Perelson (2008)
Modelling Hepatitis C virus Kinetics: The Relationship between the Infected Cell Loss rate and the Final Slope of Viral DecayAntiviral Therapy, 14
-
J. Layden-Almer, R. Ribeiro, T. Wiley, A. Perelson, T. Layden (2003)
Viral dynamics and response differences in HCV‐infected African American and white patients treated with IFN and ribavirinHepatology, 37
-
L. Rong, H. Dahari, R. Ribeiro, A. Perelson (2010)
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C VirusScience Translational Medicine, 2
-
Jeremie Guedj, Rodolphe Thiébaut, Daniel Commenges (2007)
Practical Identifiability of HIV Dynamics ModelsBulletin of Mathematical Biology, 69
-
Yong-Yuan Zhang, J. Summers (2000)
Low Dynamic State of Viral Competition in a Chronic Avian Hepadnavirus InfectionJournal of Virology, 74
-
S. Duffy, L. Shackelton, E. Holmes (2008)
Rates of evolutionary change in viruses: patterns and determinantsNature Reviews Genetics, 9
-
A. Marcos, R. Fisher, J. Ham, M. Shiffman, A. Sanyal, V. Luketic, R. Sterling, A. Fulcher, M. Posner (2000)
Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation.Transplantation, 69 7
-
J. Harris, N. Martin, M. Modi (2001)
Pegylation: a novel process for modifying pharmacokinetics.Clinical pharmacokinetics, 40 7
-
P. Glue, J. Fang, R. Rouzier-Panis, C. Raffanel, R. Sabo, Samir Gupta, M. Salfi, S. Jacobs (2000)
Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy dataClinical Pharmacology & Therapeutics, 68
- Publisher
- Wiley
- Copyright
- © 2010 Blackwell Publishing Ltd
- ISSN
- 1352-0504
- eISSN
- 1365-2893
- DOI
- 10.1111/j.1365-2893.2010.01348.x
- pmid
- 20723038
- Publisher site
- See Article on Publisher Site
Abstract
Summary. By mathematically describing early hepatitis C virus (HCV) RNA decay after initiation of interferon (IFN)‐based antiviral therapy, crucial parameters of the in vivo viral kinetics have been estimated, such as the rate of production and clearance of free virus, and the rate of loss of infected cells. Furthermore, by suggesting mechanisms of action for IFN and ribavirin mathematical modelling has provided a means for evaluating and optimizing treatment strategies. Here, we review recent modelling developments for understanding complex viral kinetics patterns, such as triphasic HCV RNA declines and viral rebounds observed in patients treated with pegylated interferon and ribavirin. Moreover, we discuss new modelling approaches developed to interpret the viral kinetics observed in clinical trials with direct‐acting antiviral agents, which induce a rapid decline of wild‐type virus but also engender a higher risk for emergence of drug‐resistant variants. Lastly, as in vitro systems have allowed a better characterization of the virus lifecycle, we discuss new modelling approaches that combine the intracellular and the extracellular viral dynamics.
Journal
Journal of Viral Hepatitis – Wiley
Published: Dec 1, 2010